Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 1 14Phase 3 4Phase NA 2Phase 1/2 2

Status

Completed 3Terminated 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 1Other neoplasm 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Precancerous Conditions 1Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Fenretinide × Clear all
NCT00004154 2018-11-08

Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer

M.D. Anderson Cancer Center

Phase 3 Completed
111 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT01479192 2018-11-07

Fenretinide in Healthy Young Women at Genetic and Familial Risk

European Institute of Oncology

Phase 3 Terminated
20 enrolled
Tumor-Agnostic

Neoplasms

NCT00003075 2018-10-24

Fenretinide in Treating Patients With Cervical Neoplasia

M.D. Anderson Cancer Center

Phase 3 Completed
39 enrolled
GynecologicOther neoplasm

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Precancerous Conditions

NCT00002646 2012-01-05

Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer

National Cancer Institute (NCI)

Phase 3 Completed
1,500 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡